Project cooperation
Innovating Nucleic Acid Medicine with heteroduplex oligonucleotide (HDO)
HDO enables gene regulation in organs other than the liver via systemic administration by conjugating ligands tailored to the target.
- Research
Rena Therapeutics
About
Rena Therapeutics Inc. (Rena) was established in 2015 as a biotech venture focusing on a new platform technology for nucleic acid medicines, called Heteroduplex oligonucleotides (HDO) technology.
HDO has the features of DNA/RNA double-stranded oligonucleotide consisting of the antisense oligonucleotides (ASO) strand and a complementary sequence to the ASO as carrier strand which is conjugated with specific ligands. Toxicity reduction and efficient delivery are the critical elements to be realized in the HDO format by utilizing the characteristics of double stranded structure and introducing suitable ligands. Specifically, we have ligands that effectively deliver of HDO to kidney (glomeruli, podocytes and tubules), lung, muscles and immune system cells etc.
In addition to the track record of technology licensing, Rena intends to make further contributions to drug discovery and asset enhancement within companies focused on nucleic acid therapeutics.
At the EU-Japan Biotech & Pharma Partnering Conference, we hope to introduce our technology to those who are interested in our HDO technology and find partners for licensing out and collaborative research.
Business Domain / 分野
Pharmaceuticals / 医薬品
Business Type / 業種
R&D / 研究開発Academia, Techtransfer / 学術、技術移転Others / その他
Technologies / 技術
Pharmacological evaluation /薬効・薬理評価Drug delivery system(DDS) / ドラッグデリバリーシステム(DDS)
Disease Area / 疾患領域
Neurology & Psychiatry / 中枢神経、精神疾患Immunology / 免疫・炎症Metabolic diseases / 代謝Musculoskeletal System / 筋骨格系Cardiovascular /循環器Gastroenterology / 消化器Rare diseases / 希少疾患
Modalities / モダリティ
Oligonucleotide drug /核酸医薬
Additional questions
Researched company/organisation type / マッチングご希望企業・機関のタイプ
Companies and Academia etc. (Joint research and development purpose) / 企業やアカデミア等（共同での研究、開発を目的）Major pharma etc. (Out-licensing purpose) / 大手ファーマ等（アウトライセンスを目的）Companies and Entities (Providing your services or technology to your clients) / 技術・サービス（研究、開発、製造等の提供を目的）
Researched disease area / マッチングご希望の疾患領域
Oncology / がんNeurology & Psychiatryy / 中枢神経、精神疾患Immunology / 免疫・炎症Metabolic diseases / 代謝Musculoskeletal System / 筋骨格系Cardiovascular/ 循環器Gastroenterology / 消化器Dermatology and sensory system / 皮膚・感覚器Rare diseases / 希少疾患Others /その他
Researched Modality / マッチングご希望のモダリティ
Small-molecule drug/低分子医薬Peptide, Protein / ペプチド、タンパクAntibody drug / 抗体医薬Oligonucleotide drug / 核酸医薬Gene therapy/ 遺伝子治療Cell therapy / 細胞治療Others / その他
Researched Technologies / マッチングご希望の技術
Others /その他
Marketplace (4)
Project cooperation
Innovating Nucleic Acid Medicine with heteroduplex oligonucleotide (HDO)
HDO enables gene regulation in organs other than the liver via systemic administration by conjugating ligands tailored to the target.
Partnership
Innovating Nucleic Acid Medicine with heteroduplex oligonucleotide (HDO)
HDO enables gene regulation in organs other than the liver via systemic administration by conjugating ligands tailored to the target.
Project cooperation
Innovating Nucleic Acid Medicine with heteroduplex oligonucleotide (HDO)
HDO enables gene regulation in organs other than the liver via systemic administration by conjugating ligands tailored to the target.
- Early
- Research
- Technical